Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British association of dermatologists biologic interventions register (BADBIR)

Warren, R. B. et al. (2015) Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British association of dermatologists biologic interventions register (BADBIR). Journal of Investigative Dermatology, 135(11), pp. 2632-2640. (doi: 10.1038/jid.2015.208) (PMID:26053050)

Full text not currently available from Enlighten.

Abstract

Drug survival reflects a drug’s effectiveness, safety, and tolerability. We assessed the drug survival of biologics used to treat psoriasis in a prospective national pharmacovigilance cohort (British Association of Dermatologists Biologic Interventions Register (BADBIR)). The survival rates of the first course of biologics for 3,523 biologic-naive patients with chronic plaque psoriasis were compared using survival analysis techniques and predictors of discontinuation analyzed using a multivariate Cox proportional hazards model. Data for patients on adalimumab (n=1,879), etanercept (n=1,098), infliximab (n=96), and ustekinumab (n=450) were available. The overall survival rate in the first year was 77%, falling to 53% in the third year. Multivariate analysis showed that female gender (hazard ratio (HR) 1.22; 95% confidence interval (CI): 1.09–1.37), being a current smoker (HR 1.19; 95% CI: 1.03–1.38), and a higher baseline dermatology life quality index (HR 1.01; 95% CI: 1.00–1.02) were predictors of discontinuation. Presence of psoriatic arthritis (HR 0.82; 95% CI: 0.71–0.96) was a predictor for drug survival. As compared with adalimumab, patients on etanercept (HR 1.63; 95% CI: 1.45–1.84) or infliximab (HR 1.56; 95% CI: 1.16–2.09) were more likely to discontinue therapy, whereas patients on ustekinumab were more likely to persist (HR 0.48; 95% CI: 0.37–0.62). After accounting for relevant covariates, ustekinumab had the highest first-course drug survival. The results of this study will aid clinical decision making when choosing biologic therapy for psoriasis patients.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Burden, Professor David
Authors: Warren, R. B., Smith, C. H., Yiu, Z. Z.N., Ashcroft, D. M., Barker, J. N.W.N., Burden, D., Lunt, M., McElhone, K., Ormerod, A. D., Owen, C. M., Reynolds, N. J., and Griffiths, C. E.M.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Journal of Investigative Dermatology
Publisher:Nature Publishing Group
ISSN:0022-202X
ISSN (Online):1523-1747

University Staff: Request a correction | Enlighten Editors: Update this record